Goldea Capital

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen 67% Overall Response Rate (ORR) and 58% Complete Response (CR) Rate Five Patients (42%) Maintained a CR at Month 6; Four of Five CRs (80%) Ongoing Beyond Six Months, Including Two at 30+ Months and One at 24+ Months Clinical Safety and Immune Recovery Comparable to Autologous Therapies Robust AlloCAR T Cell Expansion and Persistence Documented in Responding Patients Allogeneic CAR T Treatment Initiated at a Median of Three Days After Enrollment Without Need for Leukapheresis or Bridging Therapy; 100% Received Allogeneic CAR T Product Candidates Meeting Manufacturing Specifications Enrollment...

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Written by Customer Service on June 3, 2023. Posted in Public Companies.

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearance Robust mKRAS-specific T cell responses induced in 87% of patients BOSTON, June 03, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced positive interim clinical data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy. This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS. ELI-002 was studied as a monotherapy in patients with mutant KRAS-driven tumors...

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly Zevra.), a rare disease therapeutics company, today announced that an oral presentation featuring the Phase 2 clinical trial design evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 – 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters. Zevra is a corporate sponsor of the Hypersomnia Foundation and the Beyond Sleep program. “We are proud to sponsor the Hypersomnia Foundation and the Beyond Sleepy program...

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Written by Customer Service on June 3, 2023. Posted in Public Companies.

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) – – DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial – SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) — Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin (dox), in patients with...

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, is presenting today two posters at the 2023 American Society for Clinical Oncology meeting: A poster including an analysis of circulating tumor DNA (ctDNA) data from the Phase 3 KIMMTRAK (tebentafusp-tebn) trial in HLA-A*02:01 patients with metastatic uveal melanoma (mUM) A trial-in-progress poster describing the design of the Phase 2/3 trial with...

Cleantech Power Corp. Provides Update on Failure to File Cease Trade Order

Written by Customer Service on June 3, 2023. Posted in Public Companies.

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) — Cleantech Power Corp. (formerly, Alkaline Fuel Cell Power Corp.) (the “Company” or “Cleantech”) (NEO: PWWR) (OTCQB: PWWRF) (Frankfurt: E43, WKN: A3EEHV), announces that further to its press release dated May 15, 2023, the British Columbia Securities Commission (the “BCSC”) has issued a failure to file cease trade order against the Company (“FTFCTO”) which orders that general trading, whether direct or indirect, by any person, of the securities of the Company cease, which includes trading of the shares of the Company on the NEO Exchange. The Company is diligently working with its auditors to conclude the filings at the earliest possible time. The delay in completing and filing the Company’s financial statements stems from certain accounting information that was required from Fuel Cell Power...

<div>Kayne Anderson NextGen Energy & Infrastructure Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023</div>

Kayne Anderson NextGen Energy & Infrastructure Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023

Written by Customer Service on June 2, 2023. Posted in Public Companies.

HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) — Kayne Anderson NextGen Energy & Infrastructure, Inc. (the “Fund”) (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of May 31, 2023. As of May 31, 2023, the Fund’s net assets were $388.9 million and its net asset value per share was $8.24. As of May 31, 2023, the Fund’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 637% and the Fund’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 420%. Kayne Anderson NextGen Energy & Infrastructure, Inc. Statement of Assets and Liabilities May 31, 2023 (Unaudited) (in...

Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at May 31, 2023

Written by Customer Service on June 2, 2023. Posted in Public Companies.

HOUSTON, June 02, 2023 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of May 31, 2023. As of May 31, 2023, the Company’s net assets were $1.3 billion, and its net asset value per share was $9.47. As of May 31, 2023, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 576% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 418%. Kayne Anderson Energy Infrastructure Fund, Inc. Statement of Assets and Liabilities May 31, 2023 (Unaudited) (in millions) Investments $ 1,760.6 Cash...

Atlas Global Announces Changes to Canadian Operations

Written by Customer Service on June 2, 2023. Posted in Public Companies.

CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 02, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc. (“Atlas Global”, or the “Company”) (CSE: ATL), a cannabis company with expertise across the value chain, continues to focus on cost reductions, savings and production efficiencies. In furtherance of those objectives, the Company will cease operations at its facility in Gunn, Alberta and liquidate the assets of its direct and indirect wholly-owned subsidiaries operating the site. Approximately 50 employees have been impacted by this decision. All packaging activities have been relocated to the Company’s facility in Chatham, Ontario, which now serves as the Company’s Canadian hub for the processing of domestic and EU GMP flower and oils for international markets, enabling centralized manufacturing and maximizing production capabilities. Also,...

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Second Quarter Common Stock Distribution of $0.1217 Per Share

Written by Customer Service on June 2, 2023. Posted in Dividend Reports And Estimates.

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) — Sprott Focus Trust, Inc. (Nasdaq-FUND) (the “Fund” or “FUND”) has declared a quarterly distribution of $0.1217 per share on its Common Stock. The distribution, optionally payable in additional shares of Common Stock or in cash by specific stockholder election, is to be paid on June 27, 2023 to stockholders of record at the close of business on June 12, 2023 (ex-dividend on June 8, 2023). The price of shares issued for reinvestment will be determined on June 20, 2023. The Fund currently has adopted a Distribution Policy of paying quarterly distributions on its Common Stock. Distributions are being made at the annual rate of 6% of the rolling average of the prior four calendar quarter-end net asset values (“NAVs”), with the fourth quarter distribution being the greater of 1.50% of the rolling...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice